

COMPLETE GENOMICS INC  
Form 8-K  
March 09, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2011

**COMPLETE GENOMICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34939**  
(Commission  
File Number)

**20-3226545**  
(IRS Employer  
Identification Number)

Edgar Filing: COMPLETE GENOMICS INC - Form 8-K

2071 Stierlin Court

Mountain View, California 94043

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 943-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On March 3, 2011, at a meeting of the Compensation Committee (the Committee) of the Board of Directors of Complete Genomics, Inc. (the Company), the Committee approved discretionary cash bonuses to certain of the Company's executive officers for 2010:

<b>Executive Officer and Position</b>	<b>Discretionary Bonus Amount</b>
Ajay Bansal, Chief Financial Officer	\$ 70,000
Bruce Martin, Senior Vice President of Product Development	\$ 70,000
Mark J. Sutherland, Senior Vice President of Business Development	\$ 28,000

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 9, 2011

COMPLETE GENOMICS, INC.

By: /s/ Ajay Bansal  
Ajay Bansal  
Chief Financial Officer